UNLABELLED: The aim of this study was to determine the maximum tolerated dose (MTD) and to explore the clinical response to (177)Lu-DOTA-rituximab in the treatment of patients with relapsed follicular, mantle cell, or other indolent lymphomas such as marginal zone lymphoma. METHODS: To evaluate the MTD, we adjusted the dosage of the radiopharmaceutical according to body surface area (BSA). RESULTS: The MTD using (177)Lu-DOTA-rituximab was 1,665 MBq/m(2) of BSA. Thrombocytopenia and leukopenia were the dose-limiting toxicities. Significant anemia occurred only at dose level 7 (1,850 MBq/m(2) of BSA). We observed the nadir of platelets after a median of 36 d from treatment and the nadir of granulocytes after a median of 50 d. Median time to recovery to the next lower grade of toxicity was 7 d. Nonhematologic toxicity was negligible. We observed clinical responses at all dose levels and for all lymphoma entities. Some of the responses were durable; the longest follow-up is currently over 8 y. At present, 11 patients are alive and 8 patients are disease-free. CONCLUSION: Our results demonstrate the safety and feasibility of (177)Lu-DOTA-rituximab treatment for the lymphoma entities tested in this study.
UNLABELLED: The aim of this study was to determine the maximum tolerated dose (MTD) and to explore the clinical response to (177)Lu-DOTA-rituximab in the treatment of patients with relapsed follicular, mantle cell, or other indolent lymphomas such as marginal zone lymphoma. METHODS: To evaluate the MTD, we adjusted the dosage of the radiopharmaceutical according to body surface area (BSA). RESULTS: The MTD using (177)Lu-DOTA-rituximab was 1,665 MBq/m(2) of BSA. Thrombocytopenia and leukopenia were the dose-limiting toxicities. Significant anemia occurred only at dose level 7 (1,850 MBq/m(2) of BSA). We observed the nadir of platelets after a median of 36 d from treatment and the nadir of granulocytes after a median of 50 d. Median time to recovery to the next lower grade of toxicity was 7 d. Nonhematologic toxicity was negligible. We observed clinical responses at all dose levels and for all lymphoma entities. Some of the responses were durable; the longest follow-up is currently over 8 y. At present, 11 patients are alive and 8 patients are disease-free. CONCLUSION: Our results demonstrate the safety and feasibility of (177)Lu-DOTA-rituximab treatment for the lymphoma entities tested in this study.
Authors: Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Sandra Heskamp; Carla M L van Herpen; Wim J G Oyen; Winette T A van der Graaf; Otto C Boerman Journal: Mol Oncol Date: 2014-03-21 Impact factor: 6.603
Authors: Ada H V Repetto-Llamazares; Roy H Larsen; Anna Maria Giusti; Elena Riccardi; Øyvind S Bruland; Pål Kristian Selbo; Jostein Dahle Journal: PLoS One Date: 2014-07-28 Impact factor: 3.240
Authors: Sofia H L Frost; Shani L Frayo; Brian W Miller; Johnnie J Orozco; Garrett C Booth; Mark D Hylarides; Yukang Lin; Damian J Green; Ajay K Gopal; John M Pagel; Tom A Bäck; Darrell R Fisher; Oliver W Press Journal: PLoS One Date: 2015-03-18 Impact factor: 3.240
Authors: Arne Kolstad; Tim Illidge; Nils Bolstad; Signe Spetalen; Ulf Madsbu; Caroline Stokke; Johan Blakkisrud; Ayca Løndalen; Noelle O'Rourke; Matthew Beasley; Wojciech Jurczak; Unn-Merete Fagerli; Michal Kaščák; Mike Bayne; Aleš Obr; Jostein Dahle; Lisa Rojkjaer; Veronique Pascal; Harald Holte Journal: Blood Adv Date: 2020-09-08